Larimar Therapeutics, Inc. (LRMR) Stock Score, Valuation & Financial Research

Larimar Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LRMR

Larimar Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.78. These figures are a research snapshot, not a buy or sell recommendation.

What Larimar Therapeutics, Inc. does

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Larimar Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel therapies for rare diseases using its proprietary cell-penetrating peptide (CPP) platform, and it currently relies on capital raises and financing activities to fund its operations.

Products and services

  • The company is developing nomlabofusp, a lead product candidate designed to treat Friedreich's ataxia, utilizing its proprietary cell-penetrating peptide (CPP) technology platform.

Brands and product families

  • Nomlabofusp — Lead product candidate for the treatment of Friedreich's ataxia. Source

Customer types

Patients with rare diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for clinical trial management, data collection, and the manufacturing of drug product candidates. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies developing Friedreich's ataxia therapeutics — The company faces competition from other entities developing approved or investigational therapies for Friedreich's ataxia. Source

Business strengths to evaluate

  • Proprietary cell-penetrating peptide (CPP) platform Source

Business risks and research considerations

  • Clinical trial enrollment delays and regulatory approval uncertainty Source
  • Dependence on third-party manufacturers and clinical research organizations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LRMR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.78
Market capitalization:
288.79M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -172.61M
Free cash flow:
USD -113.29M
Cash:
USD 92.69M
Total debt:
USD 4.96M
EPS:
USD -1.99

What stands out

  • Free cash flow is USD -113.29M, negative for the stored period.
  • The balance sheet shows USD 92.69M of cash versus USD 4.96M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 87.73M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LRMR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can LRMR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LRMR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for LRMR to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of LRMR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research LRMR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.